CME

This activity is supported by educational grants from Aerie Pharmaceuticals, Inc.; Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Medical Management of Glaucoma: Recent Approvals and Drugs Under Investigation

Medical Management of Glaucoma: Recent Approvals and Drugs Under Investigation

This activity is supported by educational grants from Aerie Pharmaceuticals, Inc.; Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Overview

Author(s)/Faculty: L. Jay Katz, MD; Daniel Lee, MD
Source: Healio - Ophthalmology Education Lab
Type: MonographArticles/Items: 3
Release Date: 12/20/2017Expiration Date: 12/19/2018
Credit Type: CMENumber of Credits: 0.5
Cost: FreeProvider: Vindico Medical Education
Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 70 million people affected by the condition. This activity will evaluate clinical evidence for the safety and efficacy of established, new, and emerging classes of glaucoma medications.

CME Information

page 1 of 6